Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

EVP Commercial

Bd. Co-Chair, President & CSO

EVP Research

EVP Research and Development

EVP General Counsel and Secret

EVP & General Mgr, Industrial

SVP Finance & CFO

EVP Finance CFO

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases wor...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-05-03	Premium	sold (taxes)	Premium	Premium	Premium	-
2024-05-03	Premium	acquired	Premium	Premium	Premium	-
2024-05-01	Premium	sold	Premium	Premium	Premium	EVP Commercial
2024-05-01	Premium	sold	Premium	Premium	Premium	-
2024-04-29	Premium	gifted	Premium	Premium	Premium	Bd. Co-Chair, President & CSO
2024-04-29	Premium	gifted	Premium	Premium	Premium	Bd. Co-Chair, President & CSO
2024-04-01	Premium	sold	Premium	Premium	Premium	EVP Commercial
2024-04-01	Premium	sold	Premium	Premium	Premium	-
2024-03-14	Premium	sold	Premium	Premium	Premium	EVP Research
2024-03-13	Premium	sold (taxes)	Premium	Premium	Premium	EVP Research
2024-03-13	Premium	acquired	Premium	Premium	Premium	EVP Research
2024-03-01	Premium	sold	Premium	Premium	Premium	EVP Commercial
2024-03-01	Premium	sold	Premium	Premium	Premium	-
2024-02-26	Premium	gifted	Premium	Premium	Premium	EVP Research and Development
2024-02-26	Premium	sold	Premium	Premium	Premium	-
2024-02-26	Premium	sold	Premium	Premium	Premium	-
2024-02-26	Premium	acquired	Premium	Premium	Premium	-
2024-02-26	Premium	sold	Premium	Premium	Premium	EVP General Counsel and Secret
2024-02-26	Premium	acquired	Premium	Premium	Premium	-
2024-02-23	Premium	sold	Premium	Premium	Premium	-
2024-02-23	Premium	acquired	Premium	Premium	Premium	-
2024-02-22	Premium	acquired	Premium	Premium	Premium	-
2024-02-22	Premium	sold	Premium	Premium	Premium	-

REGN - Regeneron Pharmaceuticals Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for REGN